Shopping Cart 0
Cart Subtotal
AED 0

Pulmonary Arterial Hypertension - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Pulmonary Arterial Hypertension-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension-Pipeline Review, H2 2018, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 9, 11, 20, 35, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 4 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Pulmonary Arterial Hypertension-Overview 6

Pulmonary Arterial Hypertension-Therapeutics Development 7

Pulmonary Arterial Hypertension-Therapeutics Assessment 20

Pulmonary Arterial Hypertension-Companies Involved in Therapeutics Development 32

Pulmonary Arterial Hypertension-Drug Profiles 55

Pulmonary Arterial Hypertension-Dormant Projects 244

Pulmonary Arterial Hypertension-Discontinued Products 247

Pulmonary Arterial Hypertension-Product Development Milestones 248

Appendix 259


List Of Figure

List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Acceleron Pharma Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Actelion Pharmaceuticals Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Aerogen Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Arena Pharmaceuticals Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Ascendis Pharma A/S, H2 2018

Pulmonary Arterial Hypertension-Pipeline by AVEO Pharmaceuticals Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Bayer AG, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Bial-Portela & Ca SA, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Biogen Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Bristol-Myers Squibb Co, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Camurus AB, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Capricor Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Celsion Corp, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Celtaxsys Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Chiesi Farmaceutici SpA, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Complexa Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Denovo Biopharma LLC, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Eli Lilly and Co, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Gilead Sciences Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by GlaxoSmithKline Plc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Insmed Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Insys Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Japan Tobacco Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Johnson & Johnson, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Liquidia Technologies Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by MannKind Corp, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Mezzion Pharma Co Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Nippon Shinyaku Co Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Nissan Chemical Industries Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Northern Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Novartis AG, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Peloton Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by PhaseBio Pharmaceuticals Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Pulmokine Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Reata Pharmaceuticals Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Relief Therapeutics Holding AG, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Respira Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Reviva Pharmaceuticals Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Roivant Sciences Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Serodus ASA, H2 2018

Pulmonary Arterial Hypertension-Pipeline by SteadyMed Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Suda Pharmaceuticals Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Toray Industries Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by United Therapeutics Corp, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Vicore Pharma AB, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Vivus Inc, H2 2018

Pulmonary Arterial Hypertension-Dormant Projects, H2 2018

Pulmonary Arterial Hypertension-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Pulmonary Arterial Hypertension Therapeutic Products under Development, Key Players in Pulmonary Arterial Hypertension Therapeutics, Pulmonary Arterial Hypertension Pipeline Overview, Pulmonary Arterial Hypertension Pipeline, Pulmonary Arterial Hypertension Pipeline Assessment


Companies

Acceleron Pharma Inc

Actelion Pharmaceuticals Ltd

Aerogen Ltd

Arena Pharmaceuticals Inc

Ascendis Pharma A/S

AVEO Pharmaceuticals Inc

Bayer AG

Bial - Portela & Ca SA

Biogen Inc

Bristol-Myers Squibb Co

Camurus AB

Capricor Therapeutics Inc

Celsion Corp

Celtaxsys Inc

Chiesi Farmaceutici SpA

Chugai Pharmaceutical Co Ltd

Complexa Inc

Denovo Biopharma LLC

Eli Lilly and Co

Gilead Sciences Inc

GlaxoSmithKline Plc

Insmed Inc

Insys Therapeutics Inc

Japan Tobacco Inc

Johnson & Johnson

Liquidia Technologies Inc

MannKind Corp

Mezzion Pharma Co Ltd

Nippon Shinyaku Co Ltd

Nissan Chemical Industries Ltd

Northern Therapeutics Inc

Novartis AG

Peloton Therapeutics Inc

PhaseBio Pharmaceuticals Inc

Pulmokine Inc

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Respira Therapeutics Inc

Reviva Pharmaceuticals Inc

Roivant Sciences Ltd

Serodus ASA

SteadyMed Therapeutics Inc

Suda Pharmaceuticals Ltd

Takeda Pharmaceutical Co Ltd

Toray Industries Inc

United Therapeutics Corp

Vicore Pharma AB

Vivus Inc

Pulmonary Arterial Hypertension-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension-Pipeline Review, H2 2018, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 9, 11, 20, 35, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 4 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Pulmonary Arterial Hypertension-Overview 6

Pulmonary Arterial Hypertension-Therapeutics Development 7

Pulmonary Arterial Hypertension-Therapeutics Assessment 20

Pulmonary Arterial Hypertension-Companies Involved in Therapeutics Development 32

Pulmonary Arterial Hypertension-Drug Profiles 55

Pulmonary Arterial Hypertension-Dormant Projects 244

Pulmonary Arterial Hypertension-Discontinued Products 247

Pulmonary Arterial Hypertension-Product Development Milestones 248

Appendix 259


List Of Figure

List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Acceleron Pharma Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Actelion Pharmaceuticals Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Aerogen Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Arena Pharmaceuticals Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Ascendis Pharma A/S, H2 2018

Pulmonary Arterial Hypertension-Pipeline by AVEO Pharmaceuticals Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Bayer AG, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Bial-Portela & Ca SA, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Biogen Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Bristol-Myers Squibb Co, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Camurus AB, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Capricor Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Celsion Corp, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Celtaxsys Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Chiesi Farmaceutici SpA, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Complexa Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Denovo Biopharma LLC, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Eli Lilly and Co, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Gilead Sciences Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by GlaxoSmithKline Plc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Insmed Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Insys Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Japan Tobacco Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Johnson & Johnson, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Liquidia Technologies Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by MannKind Corp, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Mezzion Pharma Co Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Nippon Shinyaku Co Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Nissan Chemical Industries Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Northern Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Novartis AG, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Peloton Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by PhaseBio Pharmaceuticals Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Pulmokine Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Reata Pharmaceuticals Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Relief Therapeutics Holding AG, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Respira Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Reviva Pharmaceuticals Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Roivant Sciences Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Serodus ASA, H2 2018

Pulmonary Arterial Hypertension-Pipeline by SteadyMed Therapeutics Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Suda Pharmaceuticals Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Toray Industries Inc, H2 2018

Pulmonary Arterial Hypertension-Pipeline by United Therapeutics Corp, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Vicore Pharma AB, H2 2018

Pulmonary Arterial Hypertension-Pipeline by Vivus Inc, H2 2018

Pulmonary Arterial Hypertension-Dormant Projects, H2 2018

Pulmonary Arterial Hypertension-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Pulmonary Arterial Hypertension Therapeutic Products under Development, Key Players in Pulmonary Arterial Hypertension Therapeutics, Pulmonary Arterial Hypertension Pipeline Overview, Pulmonary Arterial Hypertension Pipeline, Pulmonary Arterial Hypertension Pipeline Assessment


Companies

Acceleron Pharma Inc

Actelion Pharmaceuticals Ltd

Aerogen Ltd

Arena Pharmaceuticals Inc

Ascendis Pharma A/S

AVEO Pharmaceuticals Inc

Bayer AG

Bial - Portela & Ca SA

Biogen Inc

Bristol-Myers Squibb Co

Camurus AB

Capricor Therapeutics Inc

Celsion Corp

Celtaxsys Inc

Chiesi Farmaceutici SpA

Chugai Pharmaceutical Co Ltd

Complexa Inc

Denovo Biopharma LLC

Eli Lilly and Co

Gilead Sciences Inc

GlaxoSmithKline Plc

Insmed Inc

Insys Therapeutics Inc

Japan Tobacco Inc

Johnson & Johnson

Liquidia Technologies Inc

MannKind Corp

Mezzion Pharma Co Ltd

Nippon Shinyaku Co Ltd

Nissan Chemical Industries Ltd

Northern Therapeutics Inc

Novartis AG

Peloton Therapeutics Inc

PhaseBio Pharmaceuticals Inc

Pulmokine Inc

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Respira Therapeutics Inc

Reviva Pharmaceuticals Inc

Roivant Sciences Ltd

Serodus ASA

SteadyMed Therapeutics Inc

Suda Pharmaceuticals Ltd

Takeda Pharmaceutical Co Ltd

Toray Industries Inc

United Therapeutics Corp

Vicore Pharma AB

Vivus Inc